Key result
Rosiglitazone significantly reduced myocardial infarction area and arrhythmia rate compared to the I/R control group (P<0.05).
Why the study?
Does rosiglitazone reduce myocardial ischemia-reperfusion injury in a rabbit model?
Population
48 male Japanese white big-ear rabbits subjected to myocardial ischemia-reperfusion (I/R) injury
Comparison
Rosiglitazone (low dose or high dose) vs Ischemia-reperfusion without rosiglitazone and a…
Design
Preclinical, randomly divided
Follow-up
24 hours
Authors
Loading...
Hypothesis-generating in rabbit ischemia-reperfusion; leaves open translation to clinical cardioprotection.
RCT (n=48)
randomly divided
Does rosiglitazone reduce myocardial ischemia-reperfusion injury in a rabbit model?
p-value: p=<0.05
Rosiglitazone may protect against myocardial ischemia-reperfusion injury by reducing infarct size, inhibiting inflammation, and improving endothelial function in a preclinical rabbit model.
Gao et al. (2013) conducted an RCT in myocardial ischemia-reperfusion injury (n=48). rosiglitazone vs. I/R group and control group was evaluated on myocardial infarction area (p=<0.05). Rosiglitazone significantly reduced myocardial infarction area and arrhythmia rate compared to the I/R control group (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: